Status
Acquired by Amgen on April 10, 2012
Funding Received
$35 Million in 1 Round from 7 Investors
Headquarters:
South San Francisco, CA
Description:
KAI Pharmaceuticals discovers and develops novel therapeutics for cardiovascular diseases, kidney diseases and pain.
Founders:
Leon Chen, Daria Mochly-Rosen
Categories:
Medical, Biotechnology
Website:
http://www.kaipharmaceuticals.com

Company Details

Update

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.

Current Team (1)

Update
  • 782e9cdef4bc99195f42d4e250ec17c0

    Daria Mochly-Rosen

    Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board Director
    2002

Past Team (4)

Update

Board Members and Advisors (2)

Update

Investors (7)

Update

Offices/Locations (1)

Update
  • Office

    270 Littlefield Avenue

    South San Francisco, CA 94080

    USA

Images (1)

Update
  • Ec40a61a03ca5d36c4d7f6ef3c24eded